Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Giants

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Pfizer Inc. and Catalent, Inc. have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. In contrast, Catalent's expenses have surged by approximately 180%, reflecting its aggressive growth strategy.

Key Insights

• Pfizer Inc.: Despite fluctuations, Pfizer's SG&A expenses have consistently hovered around the $14 billion mark, indicating a steady operational strategy.
• Catalent, Inc.: Catalent's expenses have nearly tripled, highlighting its expansion and increased market presence.
  This comparison not only underscores the strategic differences between these two giants but also offers insights into their future trajectories.